Paper
0
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
Authors
Sun Loo,Harry Iland
Ing Tiong,David Westerman,Jad Othman,Paula Marlton,Chong Chua,Duncan Purtill,Hannah Rose,Shaun Fleming,Deepak Singhal,Anoop Enjeti,William Stevenson,Teng Ng,McCulloch Derek,Lachlin Vaughan,Robin Gasiorowski,Adam Ivey,Amanda Souza,Revati Pattani,Natasha Anstee,Rachel Koldej,David Ritchie,Sanam Loghavi,Naval Daver,Courtney DiNardo,Andrew Roberts,Carolyn Grove,John Reynolds
+27 authors
,Andrew WeiJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.